Canakinumab-associated suppression of an mTOR-related serum proteomic signature after switching from tocilizumab in Still&#39;s disease.

Ilaris (canakinumab) - Novartis

Actemra IV (tocilizumab) - Roche, JW Pharma, Chugai Pharmaceutical

Canakinumab-associated suppression of an mTOR-related serum proteomic signature after switching from tocilizumab in Still's disease. (PubMed, Rheumatology (Oxford)) - Sep 30, 2026 - No abstract available
Journal • Immunology

http://www.ncbi.nlm.nih.gov/pubmed/42811183

Atsushi Kawakami; Kazusato Hara; Kiyu Norimatsu; Shoichi Fukui; Tomohiro Koga

Sep 30, 2026